Please assess the completion status of the following clinical trial:

Trial Title: Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patient \>18 years old~* Postmenopausal status, documented by prior bilateral salpingo-oophorectomy, or absence of menses \>12 months~* Recurrent urinary tract infections as defined by 3 culture positive urine cultures in the last 12 months, or 2 positive urine cultures in the last 6 months.(Positive urine cultures defined by \>100K colony forming units of 1 or 2 bacterial species on clean catch sample, or \>1000 colony forming units of 1 or 2 bacterial species on sample via straight catheterization).~* Patients on vaginal estrogen must undergo a 1 month washout period prior to initiation of the trial.~Exclusion Criteria:~* Hematuria without appropriate workup~* Pelvic organ prolapse at or beyond the hymen~* Clinically relevant urinary retention~* Pelvic reconstructive surgery within 6 months~* Prior synthetic mesh procedure for pelvic organ prolapse or urinary incontinence~* Clinically relevant nephrolithiasis~* History of breast cancer~* Contraindication to topical estrogen therapy~* Anticoagulation therapy~* Prior pelvic or vaginal radiation therapy~* Prior gynecologic malignancy~* Undiagnosed genital bleeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaginal Estrogen Therapy Group (Type: ACTIVE_COMPARATOR): Women randomized to vaginal estrogen therapy will be offered vaginal cream conjugated estrogen (Premarin) 0.5 gm per vaginal twice weekly or estradiol (Estrace): 1gm per vaginal twice weekly
- Laser Therapy Group (Type: EXPERIMENTAL): Women randomized to the laser therapy group will undergo 3 treatments, 6 weeks apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).